DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/2zx72r/erectile) has announced the addition of the "Erectile Dysfunction - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Erectile Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Erectile Dysfunction and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Acorda Therapeutics, Inc.
- Apricus Biosciences, Inc.
- Aprogen, Inc.
- Bioheart, Inc.
- Biolab Sanus Farmaceutica Ltda.
- Corridor Pharmaceuticals Inc.
- Futura Medical Plc
- Hanmi Pharmaceuticals, Co. Ltd.
- IntelGenx Corp.
- Mezzion Pharma Co. Ltd.
- Mitsubishi Tanabe Pharma Corporation
- Monosol Rx, LLC
- NAL Pharmaceuticals Ltd.
- Pacific Therapeutics Ltd.
- Palatin Technologies, Inc.
- Pharmicell Co., Ltd.
- Sagene Pharmaceuticals, Inc.
- Suda Ltd
- Yungjin Pharm Ind. Co., Ltd.
For more information visit http://www.researchandmarkets.com/research/2zx72r/erectile